In the third quarter, Commerzbank Aktiengesellschaft FI reduced its position in AbbVie Inc. by 30.5%, selling 39,586 shares and ending the period with 90,102 shares. Based on the company’s SEC filing, the remaining stake was valued at approximately $20.9 million. This reduction contrasts with Norges Bank’s new acquisition of AbbVie shares valued around $4.3 billion in Q2 and Vanguard Group’s incremental 1.9% increase to 177.3 million shares, highlighting divergent institutional strategies toward the biopharma giant.

Analyst sentiment remains cautiously positive: Raymond James reaffirmed an outperform rating, UBS maintained neutral, and Citigroup lowered its target while keeping a neutral stance; overall consensus remains at Moderate Buy. AbbVie’s latest quarterly report showed revenue of $15.78 billion, up 9.1% year-over-year, and EPS of $1.86, beating estimates by $0.09. The company set Q4 guidance between $3.320 and $3.360 per share and is expected to deliver full-year EPS of about $12.31. On the shareholder return front, AbbVie announced a quarterly dividend increase to $1.73 per share, up from $1.64, representing an annualized payout of $6.92 and a payout ratio above 500%, with an ex-dividend date of January 16th and payment on February 17th.